Aktuellt
SENASTE
Redeye updates its estimates following Fluoguide presenting its strategic update. We judge the company’s updated strategy as interesting from both a clinical and business development perspective. While it will likely maximise FG001’s commercial potential, it will also delay clinical development, arguably diverging from Fluoguide’s previous aim to reach the market as fast as possible. Overall, we endorse the company’s updated strategy and view it as value-accretive.
LÄS MER
